Krishna Institute of Medical Sciences Limited has received listing approval from BSE and NSE for 1,98,67,549 equity shares of Rs 2 each issued to qualified institutional buyers through a qualified institutional placement. The stock exchange approvals were secured on 23 June 2026, and KIMS had previously informed the exchanges about the QIP on 19 June 2026. The disclosure was made under Regulation 30 of the SEBI Listing Regulations.
Each equity share allotted under the placement carries a face value of Rs 2. The QIP was executed in compliance with the SEBI guidelines for qualified institutional placements by listed entities. Nagajayanthi J R, company secretary and compliance officer, signed the exchange filing dated 23 June 2026.
Krishna Institute of Medical Sciences has enclosed the listing approval letters received from both BSE and NSE with the exchange submission. The equity shares carry the ISIN INE967H01025. On BSE, the scrip code is 543308, and on NSE, the security trades under the symbol KIMS.
The listing approval will enable the 1,98,67,549 equity shares to be admitted for trading on both stock exchanges. This issuance will increase the total outstanding equity share capital of KIMS.
The QIP fundraising was executed through the issuance of fresh equity shares to qualified institutional buyers. With the listing approval from both exchanges, these shares will now be available for trading on the secondary market.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.